November 8, 2026 INVESTOR NOTICE: Everest Group, Ltd. (EG) Investors with Substantial Losses May Seek to Lead Class Action Lawsuit Before December 28, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces
November 8, 2026 Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026
November 8, 2026 CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases